PrimoTrex 150mg/ml 10ml Vial by Concentrex Labs

Usage

1. Set your protocol calendar.: Before the first injection, define the intended blast duration (typically 8–16 weeks), the cruise duration (8–16 weeks), and document target weekly doses for each phase; this allows precise vial count planning with PrimoTrex at 150 mg/ml.
2. Inspect the vial.: Check PrimoTrex for visible particulate matter, unusual discolouration, or vial seal compromise; do not use the product if any of these are present. Warm the vial briefly in your hands if the oil appears viscous in cooler ambient conditions.
3. Prepare your workspace aseptically.: Wash hands thoroughly, lay a clean surface, and arrange all materials: draw needle (21 gauge), injection needle (23–25 gauge, 1–1.5 inch), alcohol swabs, and a sharps container.
4. Draw the dose.: Swab the rubber stopper with a 70 % isopropyl alcohol swab and allow it to dry. Insert the draw needle, invert the vial, and withdraw the calculated volume — for example, 1.33 ml per injection for a 200 mg twice-weekly blast dose.
5. Administer intramuscularly.: Swap to the injection needle, expel air, and inject into a suitable intramuscular site (gluteus, vastus lateralis, or deltoid). Rotate sites each injection to minimise cumulative tissue stress across long blast-and-cruise calendars.
6. Log, monitor, and adjust.: Record injection date, site, and dose after each administration. Schedule blood-work at the midpoint of each blast phase and at the end of each cruise phase; use haematocrit, lipid profile, and LH/FSH data to guide phase-transition decisions.

Warnings

Frequently asked questions

What does the cruise and blast protocol mean for Methenolone Enanthate users?

Cruise and blast is a cyclical dosing strategy where athletes alternate between a high-dose blast phase — designed to maximise lean tissue growth — and a lower-dose cruise phase focused on hormonal maintenance and recovery support. Methenolone Enanthate is commonly selected for both phases because its androgenic profile is comparatively mild, making it adaptable across the differing dose ranges each phase requires without introducing excessive androgenic load during the cruise window.

How long should the cruise phase last when running PrimoTrex Methenolone Enanthate?

Most practitioner-reported cruise phases last between 8 and 16 weeks, depending on the preceding blast duration and individual recovery markers including haematocrit, lipid panels, and subjective wellbeing. A single 10 ml vial of PrimoTrex at 150 mg/ml provides 1,500 mg total, which sustains an 8-week cruise at 200 mg per week or a 5-week cruise at 300 mg per week, making vial planning straightforward for either window.

When is the right time to switch from a blast phase back to cruising with Methenolone Enanthate?

The transition to cruise is typically triggered by blood-work benchmarks rather than a fixed calendar date: rising haematocrit above 50–52 %, declining HDL cholesterol, or elevated liver enzymes signal the body is under sufficient stress to warrant pulling back to maintenance dosing. Because Methenolone Enanthate carries a relatively low aromatisation profile, it is frequently retained as the sole compound during the cruise phase once other blasted compounds are removed.

Can PrimoTrex 10ml vials be used with insulin syringes, and what needle gauge is recommended?

PrimoTrex at 150 mg/ml is an oil-based solution and is not suited to insulin syringes, which lack the barrel volume for typical doses and cannot reliably draw viscous carrier oil. A 23–25 gauge, 1–1.5 inch needle is the standard recommendation for intramuscular administration; a larger draw needle (21 gauge) may be used to pull the solution from the vial, then swapped for the finer injection needle to reduce injection-site discomfort.

How should an opened PrimoTrex 10ml vial be stored, and how long does it remain usable?

Once punctured, a PrimoTrex vial should be stored upright at room temperature (15–25 °C), away from direct light and heat sources; refrigeration is not required and may increase solution viscosity, making drawing more difficult. The benzyl alcohol preservative system in multi-dose vials supports microbial integrity for up to 28 days after first puncture when proper aseptic technique — swabbing the rubber stopper with 70 % isopropyl alcohol before each draw — is consistently applied. (2) angle_used

Manufacturer

Concentrex Labs has developed its product portfolio around a principle of concentration specificity: rather than offering a single standardised mg/ml for each compound class, the brand engineers distinct concentration tiers designed to serve different administration contexts. PrimoTrex represents this philosophy applied to Methenolone Enanthate — the 150 mg/ml specification occupies a deliberate position between standard 100 mg/ml pharmaceutical benchmarks and higher-density formulations, addressing the practical needs of cruise-and-blast athletes who require both dose flexibility and vial efficiency over multi-month administration schedules. Within the broader Concentrex Labs injectable catalogue, PrimoTrex sits alongside compound-specific entries across the anabolic, therapeutic, and ancillary categories — each product carrying the laboratory's analytical release sequence: HPLC quantification of active pharmaceutical ingredient against label specification, LAL endotoxin testing, and in-process carrier-oil tolerability validation. The 10 ml multi-dose vial format chosen for PrimoTrex reflects the brand's assessment of how long-cycle users actually consume product, aligning vial size with the typical volume required across a full cruise block at the 200–300 mg weekly dosing range.